Stay updated on Nivolumab for Oral Proliferative Verrucous Leukoplakia Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Oral Proliferative Verrucous Leukoplakia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Oral Proliferative Verrucous Leukoplakia Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record of the safety and efficacy of Nivolumab in treating Oral Proliferative Verrucous Leukoplakia, focusing on evaluating the effectiveness of the immunotherapy drug in treating the condition and potentially reducing the risk of malignancy onset.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:49.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    42%
    Check dated 2024-05-22T21:29:46.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:32:54.000Z thumbnail image

Stay in the know with updates to Nivolumab for Oral Proliferative Verrucous Leukoplakia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Oral Proliferative Verrucous Leukoplakia Clinical Trial page.